ArQule Inc. (ARQL)

4.85
0.17 3.39
NASDAQ : Health Technology
Prev Close 5.02
Open 5.04
Day Low/High 4.78 / 5.23
52 Wk Low/High 0.97 / 7.21
Volume 1.58M
Avg Volume 1.68M
Exchange NASDAQ
Shares Outstanding 108.82M
Market Cap 548.44M
EPS -0.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

ArQule To Participate In The Annual B. Riley FBR Healthcare Conference On September 4, 2018

ArQule To Participate In The Annual B. Riley FBR Healthcare Conference On September 4, 2018

ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, CEO, and Dr.

ArQule To Present At The 20th Annual Global Investment Conference On September 5, 2018

ArQule To Present At The 20th Annual Global Investment Conference On September 5, 2018

ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, Chief Executive Officer, and Marc Schegerin, Senior Vice President, Strategy, Communication and Finance, will present at the 20 th Annual Rodman & Renshaw Global Investment Conference,...

First Week Of April 2019 Options Trading For ArQule (ARQL)

First Week Of April 2019 Options Trading For ArQule (ARQL)

Investors in ArQule Inc. saw new options begin trading this week, for the April 2019 expiration.

ArQule Announces Publication Of Preclinical Data For ARQ 531, A Reversible Inhibitor Of Both Wild Type And Mutant BTK

ArQule Announces Publication Of Preclinical Data For ARQ 531, A Reversible Inhibitor Of Both Wild Type And Mutant BTK

ArQule, Inc. (Nasdaq:ARQL), today announced the publication of preclinical study data for ARQ 531, the Company's rationally-designed, reversible inhibitor of both wild type and C481S-mutant Bruton's tyrosine kinase (BTK).

ArQule Reports Second Quarter 2018 Financial Results

ArQule Reports Second Quarter 2018 Financial Results

ArQule, Inc. (Nasdaq: ARQL) today announced its financial results for the second quarter of 2018.

First Week Of September 21st Options Trading For ArQule (ARQL)

First Week Of September 21st Options Trading For ArQule (ARQL)

Investors in ArQule Inc. saw new options begin trading this week, for the September 21st expiration.

ArQule To Report Second Quarter 2018 Financial Results On August 1, 2018

ArQule To Report Second Quarter 2018 Financial Results On August 1, 2018

ArQule, Inc. (Nasdaq: ARQL) today announced it will report financial results for the second quarter of 2018 before the market opens on Wednesday, August 1, 2018.

ArQule Announces Closing Of Public Offering And Full Exercise Of Option To Purchase Additional Shares

ArQule Announces Closing Of Public Offering And Full Exercise Of Option To Purchase Additional Shares

ArQule, Inc. (Nasdaq: ARQL) today announced the closing of its previously announced underwritten public offering of common stock, including the exercise in full by the underwriters of their option to purchase an additional 1,650,000 shares at the public...

ArQule Announces Pricing Of $60.5 Million Public Offering Of Common Stock

ArQule Announces Pricing Of $60.5 Million Public Offering Of Common Stock

ArQule, Inc. (Nasdaq: ARQL) today announced the pricing of an underwritten public offering of 11 million shares of its common stock at a price to the public of $5.

ArQule Announces Commencement Of Proposed Public Offering Of Common Stock

ArQule Announces Commencement Of Proposed Public Offering Of Common Stock

ArQule, Inc. (Nasdaq: ARQL) today announced that it has commenced an underwritten public offering, subject to market and other conditions, to issue and sell shares of its common stock.

ArQule Added To The Russell 2000® Index

ArQule Added To The Russell 2000® Index

ArQule, Inc. (Nasdaq: ARQL) today announced that it has been added to the Russell 2000 ® Index, a subset of the Russell 3000 ® Index, effective as of market closing on June 22, 2018, at the conclusion of the annual Russell US Index reconstitution.

ArQule Presents Results From Ongoing Phase 1 Dose Escalation Study Of Its Reversible BTK Inhibitor, ARQ 531

ArQule Presents Results From Ongoing Phase 1 Dose Escalation Study Of Its Reversible BTK Inhibitor, ARQ 531

ArQule, Inc. (Nasdaq:ARQL) today is presenting preliminary results from the Company's Phase 1 dose escalation study for ARQ 531, an orally bioavailable, potent and reversible inhibitor of both wild type and C481S-mutant Bruton's tyrosine kinase (BTK) in...

ArQule To Present At The JMP Securities Life Sciences Conference On June 21, 2018

ArQule To Present At The JMP Securities Life Sciences Conference On June 21, 2018

ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, Chief Executive Officer, and Dr.

ARQL Crosses Above Average Analyst Target

ARQL Crosses Above Average Analyst Target

In recent trading, shares of ArQule Inc. have crossed above the average analyst 12-month target price of $5.25, changing hands for $5.78/share.

ArQule To Present Clinical Data For Its BTK Inhibitor, ARQ 531, At The 23rd Congress Of The European Hematology Association (EHA)

ArQule To Present Clinical Data For Its BTK Inhibitor, ARQ 531, At The 23rd Congress Of The European Hematology Association (EHA)

ArQule, Inc. (Nasdaq: ARQL) today announced clinical data from the company-sponsored ARQ 531-101 Phase 1 dose escalation study in subjects with relapsed or refractory hematologic malignancies will be presented on June 15, 2018 at the EHA Congress in...

ArQule Strengthens Executive Team With Two Key Appointments

ArQule Strengthens Executive Team With Two Key Appointments

ArQule, Inc. (NASDAQ: ARQL) today announced two strategic additions to its executive team, appointing Dr.

First Week Of January 2019 Options Trading For ArQule (ARQL)

Investors in ArQule Inc. saw new options become available this week, for the January 2019 expiration.

ArQule Reports First Quarter 2018 Financial Results

ArQule Reports First Quarter 2018 Financial Results

ArQule, Inc. (Nasdaq: ARQL) today announced its financial results for the first quarter of 2018.

ArQule To Report First Quarter 2018 Financial Results On May 7, 2018

ArQule To Report First Quarter 2018 Financial Results On May 7, 2018

ArQule, Inc. (Nasdaq: ARQL) today announced it will report financial results for the first quarter of 2018 before the market opens on Monday, May 7, 2018.

ArQule To Present At The 17th Annual Needham Healthcare Conference On March 27, 2018

ArQule To Present At The 17th Annual Needham Healthcare Conference On March 27, 2018

ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, Chief Executive Officer, and Dr.

ArQule To Present Data At The 2018 American Association For Cancer Research (AACR) Annual Meeting

ArQule To Present Data At The 2018 American Association For Cancer Research (AACR) Annual Meeting

ArQule, Inc. (Nasdaq: ARQL) today announced that pre-clinical and clinical data on the company's pipeline of drug candidates will be presented at the 2018 AACR Annual Meeting taking place in Chicago from April 14-April 18.

ArQule Reports Fourth Quarter And Full Year 2017 Financial Results

ArQule Reports Fourth Quarter And Full Year 2017 Financial Results

ArQule, Inc. (NASDAQ: ARQL) today announced its financial results for the fourth quarter and full year of 2017.

ArQule To Present At The 30th Annual Roth Conference On March 12, 2018

ArQule To Present At The 30th Annual Roth Conference On March 12, 2018

ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, Chief Executive Officer, will present at the 30 th Annual Roth Conference on March 12 th, 2018, at 5:00 p.

ArQule To Report Fourth Quarter 2017 Financial Results On March 5, 2018

ArQule To Report Fourth Quarter 2017 Financial Results On March 5, 2018

ArQule, Inc. (Nasdaq: ARQL) today announced it will report financial results for the fourth quarter 2017 before the market opens on Monday, March 5, 2018.

ArQule To Present At The Leerink Partners 7th Annual Global Healthcare Conference On February 15, 2018

ArQule To Present At The Leerink Partners 7th Annual Global Healthcare Conference On February 15, 2018

ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, Chief Executive Officer, and Dr.

Roivant Sciences And ArQule Enter Into License Agreement For Derazantinib In China

Roivant Sciences And ArQule Enter Into License Agreement For Derazantinib In China

Roivant Sciences and ArQule, Inc. (NASDAQ: ARQL) today announced the initiation of a collaboration to pursue the development of derazantinib, a pan-FGFR (fibroblast growth factor receptor) inhibitor, in Greater China.

ArQule Announces Dosing In A Registrational Trial Of FGFR Inhibitor, Derazantinib, For Treatment Of Intrahepatic Cholangiocarcinoma

ArQule Announces Dosing In A Registrational Trial Of FGFR Inhibitor, Derazantinib, For Treatment Of Intrahepatic Cholangiocarcinoma

ArQule, Inc. (Nasdaq: ARQL) today announced dosing of the initial patients in a registrational trial with its FGFR inhibitor, derazantinib (ARQ 087) in FGFR2 fusion driven second-line intrahepatic Cholangiocarcinoma (iCCA).

TheStreet Quant Rating: D (Sell)